Physician profile
James Avery Rush
NPI 1992975841
$513,561.19
in general payments reported to CMS, 2019-2025
29 companies · $267K in 2025
The $267K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $16K · 2021: $9,232 · 2022: $9,991 · 2023: $84K · 2024: $115K · 2025: $267K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $376K · Travel and Lodging: $47K · Food and Beverage: $26K · Consulting Fee: $17K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $376,209.55 |
| Travel and Lodging | $47,005.10 |
| Food and Beverage | $25,607.38 |
| Consulting Fee | $17,312.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $192,200.81 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $149,304.81 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $61,114.97 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| E.R. Squibb & Sons, L.L.C. | $57,630.27 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40,625.00 | 2020-2025 | Caplyta |
| Abbvie INC. | $3,699.50 | 2021-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $1,984.48 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Alkermes, INC. | $1,479.28 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Lundbeck LLC | $1,380.96 | 2019-2025 | Rexulti |
| Axsome Therapeutics, INC. | $1,232.67 | 2022-2025 | Auvelity |
| Allergan, INC. | $416.13 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $278.88 | 2024-2025 | Spravato, Invega Sustenna |
| Sunovion Pharmaceuticals INC. | $259.05 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $255.90 | 2021-2022 | |
| Tris Pharma INC | $252.41 | 2023-2024 | Dyanavel Xr, Quillivant, Quillichew Er |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $230.58 | 2019-2024 | Nuplazid |
| Ironshore Pharmaceuticals INC. | $213.15 | 2022-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $185.74 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $173.24 | 2024-2025 | Fanapt |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $169.20 | 2019 | |
| Eisai INC. | $164.92 | 2022-2024 | |
| Corium, LLC | $74.51 | 2022 | |
| Jazz Pharmaceuticals INC. | $63.05 | 2019 | |
| Biotissue Holdings INC. | $53.96 | 2020-2023 | |
| Supernus Pharmaceuticals, INC. | $35.93 | 2023 | Qelbree |
| Almatica Pharma LLC | $27.36 | 2024 | Loreev Xr |
| Shire North American Group INC | $19.62 | 2019 | |
| Indivior INC. | $19.59 | 2024 | Perseris |
| Alfasigma USA, INC. | $15.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Rush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.